Tiziana Life Sciences – Appointment of Director February 5, 2021 – Posted in: Tiziana Life Sciences (TILS)

5th February, 2021 APPOINTMENT OF DIRECTOR Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr Thomas Adams, Ph.D. as an executive director. Dr Adams will assume the position of Head of Drug Development with immediate effect and his executive role will be to manage and oversee all matters relating to the Company’s pre-clinical and clinical…

Tiziana Life Sciences – CEO interview February 3, 2021 – Posted in: Tiziana Life Sciences (TILS), Uncategorized

3rd February, 2021 Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview Tiziana Life Sciences plc (NASDAQ:TLSA/LSE:TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced an interview with Dr. Kunwar Shailubhai, CEO and CSO, is now available. In the exclusive interview, Dr. Shailubhai discusses the positive effect of nasally administered Foralumab in COVID-19 mediated pulmonary and systemic inflammation and its potential related…

Tiziana Life Sciences – Positive Data from Clinical Study of Nasal Administration with Foralumab February 2, 2021 – Posted in: Tiziana Life Sciences (TILS)

2nd February, 2021 THIS ANNOUNCEMENT INCLUDES INSIDE INFORMATION Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil · Since the anti-inflammatory effect of the nasally administered Foralumab is through the modulation of the immune system and not by directly targeting COVID-19, this therapeutic approach might also be useful for newly identified Covid-19 variants in UK, South Africa and Brazil. · Foralumab is also the first monoclonal…

Tiziana Life Sciences – Files Registration Statement on Form F-3 with SEC January 27, 2021 – Posted in: Tiziana Life Sciences (TILS)

27th January, 2021 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces that it has filed a “universal” shelf registration statement on Form F-3 (File No. 333-252441) (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in relation to…

Tiziana Life Sciences – Updated Corporate Presentation January 26, 2021 – Posted in: Tiziana Life Sciences (TILS)

26 January 2021 Updated corporate presentation Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, has today published an updated presentation to its website at https://ir.tizianalifesciences.com/presentation providing an update with respect to an overview of its current clinical pipeline. The presentation contains no new material information but gives an overview of all of the Company’s current and active development…

Tiziana Life Sciences – AIM Delisting and Admission to the Standard Listing Segment of Main Market January 20, 2021 – Posted in: Tiziana Life Sciences (TILS)

20th January, 2021 Tiziana Life Sciences plc (“Tiziana” or the “Company”) AIM Delisting and Admission to the Standard Listing Segment of Main Market Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today provided a further update with respect to the cancellation of admission of its Ordinary Shares to trading on AIM and admission to listing of its ordinary…

Tiziana Life Sciences to Host Investor Update Call December 1, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET NEW YORK and LONDON – 1 December 2020 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO Dr. Kunwar Shailubhai will host a conference call on Wednesday, 2 December 2020 at 4:15 p.m. ET to provide updates on…

Tiziana Life Sciences – Phase 1b/2 Clinical Trial – Crohn’s Disease November 11, 2020 – Posted in: Tiziana Life Sciences (TILS)

11th November, 2020 Tiziana Life Sciences PLC (“Tiziana” or “the Company”) Phase 1b/2 Clinical Trial – Crohn’s Disease Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease First Ever Study with take-home capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody – Potential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease -Crohn’s Disease Therapeutics Market Size $4.7 Billion by…

Tiziana Life Sciences – Demerger Update and Timetable Confirmation October 29, 2020 – Posted in: Tiziana Life Sciences (TILS)

29th October, 2020 Tiziana Life Sciences PLC (“Tiziana” or the “Company”) Demerger Update and Timetable Confirmation Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that the capital reduction required to effect the demerger of StemPrintER Sciences Limited and to enable the ultimate allotment of Accustem Sciences Limited shares (the “Demerged Shares”) to shareholders in the…

Tiziana Life Sciences October 26, 2020 – Posted in: Tiziana Life Sciences (TILS)

26th October, 2020 Tiziana Life Sciences Plc (“Tiziana” or the “Company”) Exercise of options, Issue of Equity PDMR Dealing and Total Voting Rights Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and issued 329,225 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid at a price of…